Preliminary Agenda
Chair: Michal Lotem, Israel
When Mis-Translation Meets Immunotherapy
Reuven Agami
Head, Division of Oncogenomics, Netherlands Cancer Institute, The Netherlands
From jumping genes to RNA therapeutics: Retrotransposons in the tumor microenvironment
Beatrice Bodega
Principal Investigator, Professor of Molecular Biology, Co-Founder and Consultant, T-One Therapeutics, INGM and University of Milan, Italy
Biological activity and regulation of the Nonsense-mediated decay (NMD) pathway
Javier Caceres
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, UK
HNRNPH2-Related Neurodevelopmental Disorder: From Molecular Mechanisms to RNA-Based Therapeutics
Rotem Karni
Principal Investigator, Perelman School of Medicine, University of Pennsylvania, USA
Turning junk into gems: Long non-coding RNAs unlock new therapeutic horizons
Alessandro Bonetti
Director, Early Respiratory, AstraZeneca, Cambridge, UK
Rethinking mechanisms of mRNA vaccine immunity
Brian D. Brown
Director, Icahn Genomics Institute; Vice Chair, Department of Immunology and Immunotherapy,
Icahn School of Medicine at Mount Sinai, USA
The roles of protein-RNA feedback in cellular homeostasis
Jernej Ule
Centre Director and Professor of Neurodegeneration Research; Francis Crick Institute and
King’s College London, UK
Decoding the RNA-Binding Protein Network in Muscle Fiber Formation: Implications for Health and Disease
Imed Gallouzi
Chair of the Center of Excellence for Smart Health at KAUST, Thuwal, Saudi Arabia
TBD
Amanda E. Hargrove
Canada Research Chair in RNA-Targeted Drug Discovery, Director, Centre for Medicinal Chemistry, University of Toronto, Canada
TBD
Kathy Liu
Principal Investigator, Associate Professor, Department of Biochemistry & Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Chair: Rotem Karni, USA
Manipulating leukocytes function with RNAs via targeted lipid nanoparticles: from concept to the clinic
Dan Peer
Director of the Laboratory of Precision NanoMedicine and Vice President for Research, Tel Aviv University (TAU), Israel
From ASO design to delivery: the TechNOA platform applied to Urea Cycle Disorders (UCD
Ernesto Guccione
Principal Investigator, The Guccione Lab, Icahn School of Medicine at Mount Sinai, USA
TBD
Caroline Robert
Head, Dermatology, Director of the Adaptive Resistance Team, Gustave Roussy and Paris Saclay University, France
Crossing the BBB: Delivering RNA Therapeutics for CNS Disorders
Saul Martinez Montero
Executive Director, RNA Therapeutics, Dyne Therapeutics
Chair: Caroline Robert, France
TBD
Claudio Sette
Principal Investigator, Catholic University of the Sacred Heart, School of Medicine, Italy
Discovery of a new class of RNA-binding proteins
Matthias Hentze
Director, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
TBD
Michal Lotem
Head of the Hadassah Cancer Research Institute (HCRI), Hadassah Hebrew University Medical Center, Jerusalem, Israel
TBD
WuxiApptec
